Your browser doesn't support javascript.
Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
Leuk Lymphoma ; 48(11): 2172-8, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17990179
Mantle cell lymphoma constitutes one of the lymphomas with poorest prognosis at relapse with limited effective salvage regimens due to advanced age. We present results of a new salvage regimen, rituximab, gemcitabine and oxaliplatin (GEMOX-R), in 14 patients with relapsing (n = 9) or refractory (n = 5) mantle cell lymphoma. The median number of cycles was 5.5 for a total of 72 cycles evaluated in the current study. The median age was 69.5 years with high-risk features. Patients received a mean number of prior treatment lines of 1.79. Sixty-four percent achieved CR (total response rate of 85%). With a median follow-up of 11 months, OS and PFS were 58% and 45% at 12 months. The major toxicity was thrombopenia grade III-IV (35%). Factors related with overall survival were ECOG performance status and a-IPI at GEMOX-R. We conclude that GEMOX-R displays an outstanding efficacy with an excellent toxicity profile in a pretreated elderly population.





Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Compostos Organoplatínicos / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Célula do Manto / Desoxicitidina / Anticorpos Monoclonais Tipo de estudo: Ensaio clínico controlado Aspecto clínico: Etiologia / Prognóstico / Terapia Limite: Adulto / Idoso / Feminino / Humanos / Masculino / Meia-Idade Idioma: Inglês Revista: Leuk Lymphoma Assunto da revista: Hematologia / Neoplasias Ano de publicação: 2007 Tipo de documento: Artigo País de afiliação: Espanha